Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

SHANGHAI and HARTFORD, Conn., May 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced the appointment of Ms. Kathryn Gregory as Vice President and Head of Corporate Business Development, reporting to Mr. John F. Chin, Chief Business Officer of Antengene. In this role, Kathryn will be responsible for leading external business development including in/out-licensing, co-development/commercialization, mergers and acquisitions, and other collaboration agreements supporting Antengene's objectives.

Ms. Kathryn Gregory
Ms. Kathryn Gregory

 

Kathryn has over 25 years of executive leadership experience in the global biopharmaceutical industry. She has extensive experience in international business development including corporate strategy, negotiation, mergers and acquisitions, alliance management; and operational experience in marketing, strategic sourcing and procurement. Prior to joining Antengene, Kathryn was the Chief Business Officer at Aileron Therapeutics. During her tenure, she led negotiations for regional partnerships in Europe and Asia for anti-cancer and chemoprotection programs and developed key relationships with large pharmaceutical and biotechnology firms. Previously, she was the President of KG BioPharma Consulting LLC, a strategic advisory company, where she assisted biopharma companies in a range of corporate strategy and business development activities. Prior to her consulting career, Kathryn was the Co-Founder, CEO and CBO of Seneb BioSciences.

Adopting a R&D strategy that leverages both in-house discovery and in-licensing, Antengene has in the four years since its establishment, built a pipeline of thirteen drug candidates with first-in-class or best-in-class potentials, covering the three therapeutic areas of oncology,autoimmune diseases, and viral infections. Just this month, Antengene entered into an agreement with Calithera Biosciences, Inc. to in-license a potent and highly selective inhibitor of CD73 (ATG-037).

Dr. Jay Mei, Founder, Chairman and CEO of Antengene, said: "Leveraging our combinatory and complimentary global business development strategy, proven capabilities in clinical and translational development, and efficient execution and operation, Antengene is presently in rapid transition from clinical-stage to commercial-stage, and has established extensive presence in the APAC region. In the past four years, we built a pipeline of thirteen drug candidates, obtained fifteen clinical trial approvals, and submitted New Drug Applications in five APAC markets. Kathryn is an exceptional leadership talent in the biopharmaceutical industry. I am confident that under her leadership, we will be able to further expand our pipeline, and soon make our novel therapeutics available to patients in the APAC region and around the world."

"Antengene has built a robust and highly innovative pipeline of thirteen drug assets mostly focused on oncology. Now we are preparing for the commercialization of selinexor across Asia Pacific markets as we expect to see regulatory approvals in Q4 of this year and Q1 of next year. I am very happy that Kathryn has joined our team. I believe her experience will make significant contributions to our business development initiatives," said Mr. John F. Chin, Chief Business Officer of Antengene.

"I am very excited to join Antengene's team of high caliber scientists and international management executives who have a wealth of experience developing and commercializing cancer medicines globally. I look forward to contributing to the rapid growth of the company by building strategic partnerships for additional first in-class/best in-class innovative assets," said Ms. Kathryn Gregory.

Kathryn received an M.B.A. degree from Pepperdine University and a B.A. degree from the University of California, Berkeley.

About Antengene

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading clinical-stage R&D driven biopharmaceutical company focused on innovative medicines for oncology and other life-threatening diseases. Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since its establishment in 2017, Antengene has built a broad and expanding pipeline of clinical and pre-clinical stage assets through partnerships as well as in-house drug discovery, and obtained 15 investigational new drug (IND) approvals and submitted 5 new drug applications (NDA) in multiple markets in Asia Pacific. Antengene's vision is to "Treat Patients Beyond Borders". Antengene is focused on and committed to addressing significant unmet medical needs by discovering, developing and commercializing first-in-class/best-in-class therapeutics. For more information, please visit: www.antengene.com.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

Related Links :

http://www.antengene.com

http://www.antengene.com

Tags:
Look out for further updates on our Facebook fan page!

Related Articles

  • 【職場熱話】發夢老細喺自己面前跳落街 有咩寓意? 網民:你真係好唔鍾意你老細!

    相信很多打工仔都曾夢到過與工作相關的人和事,發夢上班、工作、開會等等。又有沒有發夢見過自己不喜歡的上司或同事在自己眼前死掉了?這會是憎恨?壓力大?還是有甚麼其他寓意呢?

  • 【政府工略】醫療輔助隊請二級工人 公務員起薪$13,730 只須小六學歷

    醫療輔助隊最近招聘人手,二級工人入職條件不高,而且是公務員職位,月薪由第一標準薪級表第0點(每月港幣13,730元)至第一標準薪級表第8點(每月港幣16,175元),假如你正尋找一份穩定的工作,不妨一試。按圖了解申請詳情︰

  • 【政府工略】做懲教署教導員有乜要求?起薪$21,780 仲係公務員?

    懲教署定期都會有職位空缺,除了比較熟悉的懲教助理、懲教主任等,有時都會招聘不同範疇的教導員,指導在囚人士相關的技術。假如你有以下的工作經驗,並符合入職條件,可於2021年6月3日前遞交申請表格,成為懲教署教導員,以公務員條款聘用,月薪由一般紀律人員(員佐級)薪級表第3點(每月21,780元)至一般紀律人員(員佐級)薪級表第20點(每月36,745元)。

  • 【返工血淚史】日日返工搭車出晒汗 打工仔嚴選7大最悶熱港鐵站

    雖然現在只是5月,不過香港高溫持續,打工仔要在酷熱天氣下出勤,難免出現「大汗疊細汗」的慘況。以乘搭港鐵為例,不是每個港鐵站均設有冷氣,部分月台為地面或架空車站,空氣翳焗得令人頭昏腦脹。究竟哪些港鐵站被網民稱為最悶熱、最地獄的車站呢?

  • 【職場文化】世界上4成工作都是可有可無?盤點5個沒有意義的崗位

    你有沒有問過自己,到底現在的工作有何意義?美國人類學家David Graeber曾經提出超過一半的社會工作是可有可無的,他認為自由市場的興起是造成這些「狗屁工作」泛濫的主因。他提出了以下5種沒有意義的崗位,你又同意嗎?

  • 【政府工略】海關督察非全年招聘?起薪$41,380 有乜入職要求?

    過往,香港海關是不少大專生畢業後最想加入的政府部門,除了入職要求較低、更容易投考的普通關員,能力較高的求職者都希望成為海關督察。可是海關督察並非全年招聘,所以香港海關一推出職位空缺,隨即吸引一眾打工仔應徵。假如你對海關督察一位有興趣,現在有機會了!

  • 【職場文化】移民去做藍領 定係香港做白領? 網民:做藍領搵到食我又唔介意呀!

    近年香港社會運動不斷,不少打工仔都動了移民的念頭,或許到一個新的地方發民,會比較自由吧!不過,人生路不熟,在一個新地方中從頭開始,又會是件容易事情嗎?不少打工仔在考慮,到外國後,自己可以做甚麼工作呢?

  • 【綠置居2021】啟鑽苑居屋位置、價錢、尺寸、申請資格 最平首期幾多錢?5.21正式派表!

    為協香港市民自置居所,政府推出《綠表置居計劃》(簡稱︰綠置居),而最新一期的綠置居料今年5月接受申請,居屋屋苑包括鑽石山站上蓋的啟鑽苑,以及柴灣蝶翠苑和青衣青富苑合只523伙貨尾單位,連同約800個回收的租置計劃屋邨單位一併出售。在總共3,400個單位中,鑽石山啟鑽苑的首期最平,只須$59,000即可上車,定價則為118萬至385萬元,相信又會吸引一眾希望上樓的市民入手。

  • 【返工血淚史】搭升降機無人肯撳掣 打工仔︰極度自私!

    自從新冠肺炎爆發後,香港人擔心透過公共用品感染病毒,因此每次接觸過所有物件後,都會用消毒酒精清楚雙手,有人甚至購買或自製神器,避免雙手沾上病毒。有衛生防疫意識絕對是好事,但影響到其他人的話,那又是否自私的行為呢?讀者B小姐最近投稿表示,公司大樓的打工仔搭𨋢經常不撳掣,有時甚至不按實開門,其他人未入𨋢,亦隨門關上,B小姐大鬧︰「極度自私!」

  • 【職場熱話】撩鼻屎、咬手指、捽眼……網民大數污糟同事六宗罪

    肺炎疫情持續,保持個人衛生是最基本的預防方法。可惜不是每個人都有公德心,在辦公室狹窄環境內傳播病毒。近日有網民在討論區大數污糟男同事的惡行,不但常常在人前撩鼻屎、咬手指皮,更惡人先告狀,反指事主「唔鍾意咪擰咩面」,令人側目。